Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Turbinaria decurrens extract (TDE) is a research-stage botanical product derived from the brown macroalgae *Turbinaria decurrens Bory*. It contains bioactive compounds such as the carotenoid fucoxanthin and the sulfated polysaccharide fucoidan. Research, primarily conducted by academic institutions like Universitas Indonesia, has demonstrated its potential antiproliferative and apoptotic effects against various cancer cell lines, including HeLa (cervical cancer) and HCT-116 (colon cancer). Additionally, the extract exhibits antioxidant, anticoagulant, and anti-HIV activities. It is currently in the preclinical/research stage and has not undergone formal clinical development or regulatory approval.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on turbinaria decurrens extract.